



UNDERSTANDING YOUR TREATMENT

Retatrutide

A physician's guide to the first triple-agonist peptide for weight management

  INVESTIGATIONAL — NOT FDA-APPROVED. Retatrutide (LY3437943) is a first-in-class triple GLP-1/GIP/glucagon receptor agonist (39 amino acids) developed by Eli Lilly. Adding glucagon receptor agonism to the dual-agonist paradigm is hypothesized to enhance weight loss through hepatic lipid mobilization.

HOW IT WORKS

1

Compound Class

Triple Receptor Agonist (GLP-1/GIP/Glucagon)

2

Clinical Weight Loss

Up to 24.2% body weight at 48 weeks (Phase 2)

3

Half-Life

~6 days (estimated)

Talk to your prescriber about whether Retatrutide may be right for you

This compound is available by prescription only



WHAT RESEARCHERS HAVE FOUND

Phase 2 — Retatrutide for Obesity

1,281-patient trial showed 12mg dose achieved 24.2% mean weight loss at 48 weeks. 100% of patients on 12mg lost at least 5% body weight. The highest weight loss in any obesity trial.

New England Journal of Medicine, 2023

Phase 2 — Retatrutide for Type 2 Diabetes

Significant HbA1c reductions and weight loss across all dose groups in patients with T2D, demonstrating dual benefit for metabolic disease.

Lancet, 2023

QUESTIONS TO ASK YOUR PROVIDER

- ? What currently approved alternatives offer the closest efficacy to retatrutide's Phase 2 results while we await approval?
- ? What should I monitor regarding the novel dysesthesia signal (20.9% at 12 mg) detected in Phase 3?
- ? Does the Phase 2a MASLD data (-82.4% liver fat) suggest liver-specific benefits beyond weight loss alone?
- ? How should I counsel patients asking about obtaining retatrutide from online or compounding sources?
- ? Does the glucagon component's theoretical energy expenditure benefit translate to clinically meaningful additional weight loss?

IMPORTANT SAFETY INFO

GI side effects (nausea, diarrhea, vomiting) are dose-dependent and typically improve with slow titration

Same MTC/MEN2 contraindications as other GLP-1 receptor agonists

Monitor for pancreatitis symptoms

Long-term safety data still being collected in Phase 3 trials

Have Questions?

Eternal Beauty Medical Aesthetics

9032789566

<https://www.eternalbeautytexarkana.com>

This is a compounded preparation and is NOT an FDA-approved product. It is prepared by a licensed pharmacy based on a prescription from your healthcare provider. The safety and efficacy of this compounded preparation have not been established by the FDA.

This information is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any new medication.